bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) is one of 36 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers? We will compare bioAffinity Technologies to related companies based on the strength of its analyst recommendations, profitability, risk, dividends, valuation, earnings and institutional ownership.
Risk and Volatility
bioAffinity Technologies has a beta of 3.93, indicating that its share price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ peers have a beta of 6.29, indicating that their average share price is 529% more volatile than the S&P 500.
Profitability
This table compares bioAffinity Technologies and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
bioAffinity Technologies | -313.34% | -107.20% | -84.10% |
bioAffinity Technologies Competitors | -277.19% | -24.82% | -13.79% |
Institutional and Insider Ownership
Earnings & Valuation
This table compares bioAffinity Technologies and its peers gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
bioAffinity Technologies | $2.53 million | -$7.94 million | -2.63 |
bioAffinity Technologies Competitors | $1.50 billion | $86.53 million | 6.82 |
bioAffinity Technologies’ peers have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a summary of recent ratings for bioAffinity Technologies and its peers, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
bioAffinity Technologies Competitors | 36 | 654 | 1083 | 30 | 2.61 |
As a group, “Commercial physical research” companies have a potential upside of 15.05%. Given bioAffinity Technologies’ peers higher possible upside, analysts clearly believe bioAffinity Technologies has less favorable growth aspects than its peers.
Summary
bioAffinity Technologies peers beat bioAffinity Technologies on 9 of the 10 factors compared.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.